Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab.pdf (1.55 MB)
Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab.
journal contributionposted on 2019-07-08, 08:42 authored by L George, A Wright, V Mistry, A Sutcliffe, L Chachi, K Haldar, MY Ramsheh, M Richardson, R van der Merwe, U Martin, P Newbold, CE Brightling
We hypothesized whether the reduction in eosinophilic airway inflammation in patients with chronic obstructive pulmonary disease (COPD) following treatment with benralizumab, a humanized, afucosylated, monoclonal antibody that binds to interleukin-5 receptor α, increases the airway bacterial load. Analysis of sputum samples of COPD patients participating in a Phase II trial of benralizumab indicated that sputum 16S rDNA load and Streptococcus pneumoniae were reduced following treatment with benralizumab. However, in vitro, eosinophils did not affect the killing of the common airway pathogens S. pneumoniae or Haemophilus influenzae. Thus, benralizumab may have an indirect effect upon airway bacterial load.
Editorial support was provided by Cactus Communications and by Michael A Nissen, ELS, of AstraZeneca. This support was funded by AstraZeneca. This work was funded in part by Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling (AirPROM) project (funded through the European Union’s Seventh Framework Programme [FP7] grant), the National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Centre, and MedImmune Ltd.
CitationInternational Journal of Chronic Obstructive Pulmonary Disease, 2019, 14, pp. 1177-1185
Author affiliation/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Infection, Immunity and Inflammation
- VoR (Version of Record)